Story perspectives
FDA Approves Lynkuet: First Nonhormonal Menopause Treatment
10/24/2025
1 of 1
Story summary
- U.S. Food and Drug Administration approved elinzanetant, branded Lynkuet, to treat menopausal hot flashes and night sweats.
- Lynkuet is the first nonhormonal drug that blocks neurokinin 1 receptor (NK1) and neurokinin 3 receptor (NK3).
- Trials show major improvements, with over 80% reporting at least a 50% decrease after 26 weeks.
- Common side effects are headache and fatigue.
- Lynkuet is expected to be available in the United States by November 2025.
